Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Chemotherapy and Stem Cell Transplant with Immunomodulation in High-Risk Breast Cancer
NCT00008203Phase 3Completed
- Sponsor
- Herbert Irving Comprehensive Cancer Center
- Start
- May 1996
- Primary completion
- Dec 2005
- Modality
- Cytokines & Interferons, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Cyclosporine + Interferon gamma with Interleukin-2 (2 arms). Primary endpoints: Tumor Response, Disease-Free Survival at 5 years and 2 more. Started May 1996; status: completed.
02
Drugs
cyclosporineinterferon gamma-1baldesleukin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00008203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00008203.